Clinical Trials Logo

KRAS Activating Mutation clinical trials

View clinical trials related to KRAS Activating Mutation.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04470674 Withdrawn - Lung Cancer Clinical Trials

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Start date: April 6, 2021
Phase: Phase 2
Study type: Interventional

This is a two arm, randomized, phase II study of patients with advanced KRAS mutation positive and PD-L1 high NSCLC who have not received therapy for advanced stage disease. Patients will be randomized between Arm A and Arm B treatment. Arm A treatment will consist of durvalumab every 4 weeks for 13 cycles. Arm B treatment will consist of durvalumab with chemotherapy every 3 weeks for 4 cycles followed by durvalumab with pemetrexed every 3 weeks for 13 cycles.